|
|
|
|
BioInvent, ThromboGenics Initiate Patients Enrollment For Deep Vein Thrombosis
Study to assess safety and efficacy of three escalating doses of TB-402 BioInvent and ThromboGenics have initiated the enrollment of second cohort of patients for their phase-II trial of TB-402.TB-402 is a novel, long acting anticoagulant...
|
|
|
Medical News: ThromboGenics And BioInvent Start Recruitment Of Second 100 Patient Cohort In Phase II DVT Proph
Patient / Public: Health Professional: Article Opinions: ThromboGenics NV (Euronext Brussels: THR) and co-development partner BioInvent International (OMXS: BINV) announce that they have started recruitment of a second cohort of patients for...
|
|
|
ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study w
3342 live jobs on PharmiWeb.com now Leuven, Belgium and Lund, Sweden?July 3, 2009? ThromboGenics NV (Euronext Brussels: THR) and co-development partner BioInvent International (OMXS: BINV) announce that they have started recruitment of...
|
|
|
ThromboGenics And BioInvent Start Recruitment Of Second 100 Patient Cohort In Phase II DVT Prophylaxis Study W
ThromboGenics NV (Euronext Brussels: THR) and co-development partner BioInvent International (OMXS: BINV) announce that they have started recruitment of a second cohort of patients for their Phase II trial of TB-402.This follows...
|
|
|
Fatal overdose after leaving hospital
A SUICIDAL patient who walked out of the Whittington Hospital because he thought the nurses were trying to kill him later took an overdose at his hostel.An inquest heard on Tuesday how disabled Vincent Collin, 37, of the Arundel Project,...
|
|
|
ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study W
LEUVEN, Belgium The Phase II trial is an active (enoxaparin)-controlled, dose-escalating, multicenter, prospective, randomised, open label trial evaluating TB-402 for the prophylaxis of DVT after knee surgery.The study is assessing three...
|
|
|
BioInvent and ThromboGenics Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study w
- BioInvent International AB (OMXS: BINV) and ThromboGenics NV (Euronext Brussels: THR) announce that they have started recruitment of a second cohort of patients for their Phase II trial of TB-402.This follows completion of recruitment...
|
|
|
ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study W
LEUVEN, Belgium and LUND, Sweden, July 3 /PRNewswire-FirstCall/ -- ThromboGenics NV and co-development partner BioInvent International (OMXS: BINV) announce that they have started recruitment of a second cohort of patients for their Phase II...
|
|
|
ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study W
LEUVEN, Belgium and LUND, Sweden, July 3 /PRNewswire-FirstCall/ -- ThromboGenics NV and co-development partner BioInvent International (OMXS: BINV) announce that they have started recruitment of a second cohort of patients for their Phase II...
|
|
|
ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study W
LEUVEN, Belgium and LUND, Sweden, July 3 /PRNewswire-FirstCall/ -- ThromboGenics NV and co-development partner BioInvent International (OMXS: BINV) announce that they have started recruitment of a second cohort of patients for their Phase II...
|
|
|
Using Thrombophilia Testing to Determine Anticoagulation Duration in Pediatric Thrombosis is not Cost-Effectiv
(Click the title below to leave the MDLinx Network and go to the Journal's Website) The Journal of Pediatrics, 07/01/09 Print Save in My Library Free Abstract O'Brien SH et al.- Universal thrombophilia testing after a first episode of...
|
|
|
New peripherally inserted central catheter mimics nature
A novel coating being used on a new peripherally inserted central catheter (PICC) from r4 Vascular mimics the cell layer found on natural tissue surfaces.r4 Vascular designed the catheter to have a biomimetic surface that mimics the...
|
|
|
Physicians Maintain Delicate Balance with Antiplatelet, Anticoagulant Therapy
In an aging population, cardiologists are increasingly required to manage patients with comorbidities that call for combining antiplatelet and anticoagulant preventive therapies.Treading the narrow path between effective ischemic...
|
|
|
Rex Medical Option Retrievable Vena Cava Filter Receives 510k Clearance and CE Mark Approval
- (NewsRx.com) -- Rex Medical, L.P.announced that it has received 510(k) Clearance from the U.S. Food and Drug Administration (FDA) along with CE Mark Approval for the Option Retrievable Vena Cava Filter in the prevention of recurrent...
|
|
|
SVG occlusion not linked to anti-heparin/PF4 antibodies
MedWire News: Antibodies to heparin and platelet factor 4 (PF4) complexes are not independently associated with early saphenous vein graft (SVG) occlusion or adverse clinical outcomes after coronary artery bypass graft (CABG) surgery,...
|
|
|
729 Deep Vein Thrombosis
Veins get no respect.Millions of Americans worry about heart attacks, which occur when arteries are blocked by a blood clot. But blood clots in veins get very little attention, although they can also be life threatening. ...
|
|
|
PMT Adoption Will Accelerate Due to Treatment of DVT
According to Millennium Research Group (MRG), the pharmacomechanical thrombectomy procedure (PMT) adoption will accelerate over the next five years due to growing physician interest in treating deep vein thrombosis (DVT).
|
|
|
Pharmacomechanical Thrombectomy Procedure Adoption to Accelerate Due to Treatment of DVT
According to Millennium Research Group (MRG), the pharmacomechanical thrombectomy procedure (PMT) adoption will accelerate over the next five years due to growing physician interest in treating deep vein thrombosis (DVT).
|
|
|
Intrauterine subdural hemorrhage in a preterm neonate possibly associated with maternal low-molecular weight h
4Children's Hospital, Klinikum, Konstanz, Germany Correspondence: Dr P Gessler, Children's Hospital, Klinikum, Luisenstrasse 7, D-78461 Konstanz, Germany.E-mail: peter.gessler@klinikum-konstanz.de Abstract We report intrauterine subdural...
|
|
|
Med Device Industry Overlooks Peripheral Vasc Disease Ops, Scientia Advisors Finds
CAMBRIDGE, Mass & PALO ALTO, Calif.-(Business Wire)-June 25, 2009 - New technologies for diagnosing and treating peripheral vascular disease (PVD) present importantand largely overlookedopportunities for medical device companies,...
|
|
|
DVT risk increases with proximity to major road traffic
MedWire News: Researchers highlight the impact of air pollution on risk for venous thrombosis, finding that living near major roads significantly increases the likelihood of deep vein thrombosis (DVT).Our findings,...
|
|
|
ASMBS: VTE Risk Persists for a Year After Bariatric Surgery
DALLAS, June 25 -- The risk of venous thromboembolism (VTE) after bariatric surgery persists for at least a year after the procedure, according to a review of medical records of 17,000 patients.The incidence of VTE rose from 0.88% during...
|
|
|
High-Stakes Nursing
Becky Goddard, MSN, RN, jokes that it should be a prerequisite that all neurosurgical nurses are 'a little anal-retentive.' The Neurologic & Orthopedic Hospital of Chicago (NOHC) nurse laughs at her own observation; but in a business...
|
|
|
Prevention and treatment of venous thromboembolism in older people
(Click the title below to leave the MDLinx Network and go to the Journal's Website) Reviews in Clinical Gerontology, 06/23/09 Print Save in My Library Free Abstract Veiraiah A et al.- The incidence of deep vein thrombosis (DVT...
|
|
|
Arguments About Accountability May Have Dire Impacts for Drugmakers and Patients
By Ilene Schneider BioWorld Perspectives Contributing Writer Who is responsible for drug safety?Should a pharmaceutical company have to empty its deep pockets when the FDA has approved the use of its drug in a certain manner clearly...
|
